ClinicalTrials.gg
CompletedNCT07554196Updated Apr 28, 2026

A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of HH-101 (0.3 mg/kg) and HH-101 (1 mg/kg ) in Solid Tumor, sponsored by Huahui Health. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Huahui Health · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 2 months after the study started (first participant enrolled Jan 2022, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this study is to evaluate the safety of HH-101 antibody, administered as monotherapy to participants with advanced solid tumors.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Huahui Health is the lead sponsor of 18 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary signing of the written form;
  • Histologic or cytologic confirmation of advanced solid tumor;
  • (ECOG) performance status score of 0 or 1;
  • Have an estimated ≥3 Months, in the judgement of the investigator;
  • Must have at least 1 as defined by the (RECIST 1.1).

Exclusion criteria

Exclusion Criteria:

  • History of other within 5 years prior to the first dose of study drug, except for malignancies that have been cured after treatment, such as thyroid cancer, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ of the breast.
  • Receipt of the last systemic anti-tumor therapy within 2 weeks prior to the first dose of study drug, including chemotherapy, radiotherapy, targeted therapy, or traditional Chinese herbal medicine or patent Chinese medicines with anti-tumor activity. Patients who received tumor therapy within 4 weeks prior to the first dose of study drug.
  • Adverse reactions from previous treatments that have not recovered to v5.0 Grade 1 or lower (except for alopecia and neuropathy, which, in the Investigator's judgment, are long-standing and not expected to recover).
  • Prior hematopoietic stem cell transplantation or solid organ transplantation.
  • If female, is pregnant, breastfeeding, or planning to become pregnant.
  • Known to HH-101 Injection or any of its components. History of severe hypersensitivity reactions to other therapeutic antibody drugs. Known allergy to multiple substances or history of severe allergic diseases.
  • Known interstitial lung disease or non-infectious pneumonitis requiring therapy.
  • Other severe, acute, or chronic medical conditions, psychiatric disorders, or laboratory abnormalities that, in the Investigator's judgment, may increase the risk associated with study participation or may interfere with the interpretation of study results.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    HH-101 Dose escalation (cohort 1)

    Drug: HH-101 (0.3 mg/kg)

  • Experimental
    HH-101 Dose escalation (cohort 2)

    Drug: HH-101 (1 mg/kg )

  • Experimental
    HH-101 Dose escalation (cohort 3)

    Drug: HH-101 (3 mg/kg )

  • Experimental
    HH-101 Dose escalation (cohort 4)

    Drug: HH-101 (10 mg/kg)

Interventions

  • DrugHH-101 (0.3 mg/kg)

    Participants received 0.3 mg/kg HH-101 as an intravenous (IV) infusion on day (D)1 and D21 of each 21-day cycle every 3 weeks (Q3W).

  • DrugHH-101 (1 mg/kg )

    Participants received 1 mg/kg HH-101 as an intravenous (IV) infusion on day (D)1 and D21 of each 21-day cycle every 3 weeks (Q3W).

  • DrugHH-101 (3 mg/kg )

    Participants received 3 mg/kg HH-101 as an intravenous (IV) infusion on day (D)1 and D21 of each 21-day cycle every 3 weeks (Q3W).

  • DrugHH-101 (10 mg/kg)

    Participants received 10 mg/kg HH-101 as an intravenous (IV) infusion on day (D)1 and D21 of each 21-day cycle every 3 weeks (Q3W).

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs) per Common Terminology Criteria for Adverse Events v6.0 (CTCAE v5.0)

    It will be assessed by the frequency, severity and nature of AEs, serious adverse event (SAE), changes in vital signs, physical examination, 12-lead ECG, laboratory tests (haematology, blood chemistry, urinalysis, coagulation Function, Thyroid Function Test and etc.), The severity of AEs will be graded by the NCI CTCAE version 5.0 and the AE terms will be coded by the current version of the Medical Dictionary for Regulatory Activities (MedDRA).

    Time frame: Baseline through safety follow up completion (Up To 24 Months)

Secondary outcomes

  1. Area under the concentration-time curve (AUC)

    Time frame: up to 24 months

  2. Maximum observed plasma concentration (Cmax).

    Time frame: up to 24 months

  3. Time to reach Cmax (Tmax).

    Time frame: up to 24 months

  4. Terminal elimination half-life (t1/2).

    Time frame: up to 24 months

  5. Objective response rate (ORR)

    Investigate preliminary antitumor activity of HH-101 as assessed by radiological response per RECIST v1.1. ORR is defined as the proportion of subjects who achieve a Complete Response (CR) or Partial Response (PR) following treatment.

    Time frame: Baseline through Measured Progressive Disease (Up To 24 Months)

  6. Disease control rate (DCR)

    Investigate preliminary antitumor activity of HH-101 as assessed by radiological response per RECIST v1.1. DCR is defined as the proportion of subjects who achieve Complete Response (CR), Partial Response (PR), or Stable Disease (SD) following treatment.

    Time frame: Baseline through Measured Progressive Disease (Up To 24 Months)

  7. Duration of response (DOR)

    Investigate preliminary antitumor activity of HH-101 as assessed by radiological response per RECIST v1.1. DOR is defined as the time from the first documentation of objective response until the first documentation of tumor progression or death from any cause.

    Time frame: Baseline through Measured Progressive Disease or death (Up To 24 Months)

  8. progression-free survival (PFS)

    Investigate preliminary antitumor activity of HH-101 as assessed by radiological response per RECIST v1.1. PFS is defined as the time from the start of treatment until the first documentation of tumor progression or death from any cause.

    Time frame: Baseline through Measured Progressive Disease or death (Up To 24 Months)

  9. overall survival (OS)

    Investigate preliminary antitumor activity of HH-101 as assessed by radiological response per RECIST v1.1. OS is defined as the time from the start of treatment until death from any cause.

    Time frame: Baseline through the date of death from any cause (Up to 24 Months)

07

Study locations

1 site
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Aug 2023, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2026
First posted
Apr 28, 2026
StartActual
Jan 19, 2022
Primary completionActual
Aug 9, 2023
CompletionActual
Mar 21, 2024
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07554196
Lead sponsor
Huahui Health
Responsible party
Sponsor
First posted
Apr 28, 2026
Start date
Jan 19, 2022
Primary completion
Aug 9, 2023
Completion
Mar 21, 2024
Last update
Apr 28, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion